Quantessence Capital LLC Invests $584,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Quantessence Capital LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 5,524 shares of the medical equipment provider's stock, valued at approximately $584,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at $25,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet in the fourth quarter worth $39,000. OFI Invest Asset Management purchased a new stake in Zimmer Biomet during the fourth quarter valued at $40,000. SRS Capital Advisors Inc. increased its position in Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 285 shares during the last quarter. Finally, Atala Financial Inc bought a new position in Zimmer Biomet in the fourth quarter valued at about $51,000. Institutional investors own 88.89% of the company's stock.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several research reports. Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Finally, Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded down $0.04 during mid-day trading on Friday, reaching $101.46. The stock had a trading volume of 1,661,962 shares, compared to its average volume of 1,669,704. The business's 50 day moving average price is $105.81 and its 200 day moving average price is $106.59. Zimmer Biomet Holdings, Inc. has a 1 year low of $93.10 and a 1 year high of $123.96. The company has a market cap of $20.07 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business posted $2.20 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.